Safety profile of atorvastatin 80 mg: A meta-analysis of 17 randomized controlled trials in 21,910 participants. Drug Saf. May 2016;39(5):409-419. PMID: 26860922. 56. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. Nov 13 2010;376(9753): 1670-1681. PMID: 21067804. 57. Wang S, Cai R, Yuan Y, Varghese Z, Moorhead J, Ruan XZ. Association between reductions in low-density lipoprotein cholesterol with statin therapy and the risk of new-onset diabetes: A meta-analysis. Sci Rep. Jan 10 2017;7:39982. PMID: 28071756. 58. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate- dose statin therapy: A meta-analysis. JAMA. Jun 22 2011;305(24):2556-2564. PMID: 21693744. 59. Pandit AK, Kumar P, Kumar A, Chakravarty K, Misra S, Prasad K. High-dose statin therapy and risk of intracerebral hemorrhage: A meta-analysis. Acta Neurol Scand. Jul 2016;134(1):22-28. PMID: 26647879. 60. McKinney JS, Kostis WJ. Statin therapy and the risk of intracerebral hemorrhage: A meta-analysis of 31 randomized controlled trials. Stroke. Aug 2012;43(8):2149-2156. PMID: 22588266. 61. Sun H, Yuan Y, Wang P, et al. Intensified low-density lipoprotein-cholesterol target of statin therapy and cancer risk: A meta-analysis. Lipids Health Dis. Nov 2 2015;14:140. PMID: 26526340. 62. Emberson JR, Kearney PM, Blackwell L, et al. Lack of effect of lowering LDL cholesterol on cancer: Meta- analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One. 2012; 7(1):e29849. PMID: 22276132. 63. Bytyci I, Bajraktari G, Bhatt DL, et al. Hydrophilic vs lipophilic statins in coronary artery disease: A meta- analysis of randomized controlled trials. J Clin Lipidol. May - Jun 2017;11(3):624-637. PMID: 28506385. 64. 